Fast and simple biomarker detection by computational microscopy

We developed a fast, sensitive biomarker detection method for early diagnosis and monitoring of cancer treatments, aiming to improve patient outcomes through preventative diagnostics.

Subsidie
€ 150.000
2024

Projectdetails

Introduction

Detection of low concentrations of biomarkers, such as low-abundant proteins in physiological samples, is crucial for early-stage diagnosis and disease monitoring. However, existing detection methods are often laborious, costly, and time-consuming, rendering them unsuitable for such applications.

Method Development

Based on advances in computational PSF engineering microscopy made during our ERC Starting Grant, and in combination with microfluidic design, we developed a simple and fast biomarker detection method. This method allows accurate and sensitive results with minimal hands-on sample processing, which we have validated for potential applicability in diagnostics, and specifically, for continuous monitoring.

Clinical Application

As a target clinical application towards which we can optimize our engineering efforts, we demonstrate the potential for preventative diagnostics via a collaboration with Rambam Medical Center (Israel), focusing on monitoring cell-based cancer treatments.

Challenges in Cell-Based Therapies

While cell-based therapies can be highly effective, they have introduced new types of cytokine-related adverse effects that can be debilitating and even life-threatening. Due to the current lack of appropriate diagnostics for preventative treatment, these adverse effects are mitigated only when symptoms arise, which might be too late.

Hypothesis and Goals

We hypothesize that earlier detection using our method will enable preventive treatment and reduction in frequency and severity of these adverse events, transforming patient outcomes.

Detection Scheme Development

We will develop a multiplexed cytokine detection scheme that reaches clinically significant sensitivity and assess the effectiveness of this approach by monitoring CAR-T patients.

Market Research and Regulation Strategy

In the duration of the project, we will conduct market research and develop a regulation strategy with the aid of industrial and medical collaborations, advancing our diagnostic method toward commercialization.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-12-2024
Einddatum31-5-2026
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYpenvoerder

Land(en)

Israel

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC STG

Detecting epigenetic biomarkers in the blood for non-invasive precision oncology

Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.

€ 1.500.000
EIC Transition

Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples

The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.

€ 2.499.999
MIT R&D Samenwerking

DETACT - Detection of Enzymes and muTAtions for Cancer Treatment

Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.

€ 215.845